The balance sheet appears vulnerable, with $2.3 million in goodwill representing approximately 22.8% of the $10.1 million in total assets as of 2025Q3.
| Total Current Assets | 7.77M | 157.81K | 6.65K | 329.54K | 304.52K |
| Cash & Short-Term Investments | 7.35M | 63.74K | 2.81K | 75.87K | 300.85K |
| Cash Only | 7.35M | 63.74K | 2.81K | 75.87K | 300.85K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 339.25K | 0 | 0 | 250K | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 2.3M | 2.3M | 2.19M | 2.21M | 736.98K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.3M | 2.3M | 2.19M | 2.21M | 736.98K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 10.07M | 2.46M | 2.19M | 2.54M | 1.04M |
| Asset Turnover | 0.00x | - | - | - | - |
| Asset Growth % | 463.83% | 12.07% | -13.65% | 143.83% | - |
| Total Current Liabilities | 92.89K | 1.25M | 1.62M | 1.36M | 15.13K |
| Accounts Payable | 0 | 63.69K | 151.26K | 8.01K | 15.13K |
| Days Payables Outstanding | - | - | - | - | - |
| Short-Term Debt | 0 | 271.75K | 1.47M | 1.35M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 92.89K | 0 | 0 | 0 | 0 |
| Current Ratio | 83.69x | 0.13x | 0.00x | 0.24x | 20.12x |
| Quick Ratio | 83.69x | 0.13x | 0.00x | 0.24x | 20.12x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 53K | 24.49K | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 53K | 24.49K | 0 | 0 | 0 |
| Total Liabilities | 145.89K | 1.27M | 1.62M | 1.36M | 15.13K |
| Total Debt | 0 | 271.75K | 1.47M | 1.35M | 0 |
| Net Debt | -7.35M | 208.01K | 1.46M | 1.27M | -300.85K |
| Debt / Equity | 0.00x | 0.23x | 2.57x | 1.14x | - |
| Debt / EBITDA | -0.00x | - | - | - | - |
| Net Debt / EBITDA | 0.98x | - | - | - | - |
| Interest Coverage | -1.98x | -15.54x | -8.28x | -23.57x | - |
| Total Equity | 9.93M | 1.19M | 571.72K | 1.18M | 1.03M |
| Equity Growth % | 1379.28% | 107.33% | -51.52% | 14.89% | - |
| Book Value per Share | 0.17 | 0.06 | 0.03 | 0.06 | 0.05 |
| Total Shareholders' Equity | 9.93M | 1.19M | 571.72K | 1.18M | 1.03M |
| Common Stock | 7.03K | 2.71K | 1.51K | 855.89K | 104.49K |
| Retained Earnings | -19.79M | -10.56M | -3.92M | -3.22M | -2.62M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and dilution
As reported in financial statements, Klotho Neurosciences has experienced extreme volatility in its equity base, which plummeted from $50.8 million in 2023Q3 to a deficit in 2024Q2, before recovering to $9.9 million by 2025Q3, largely driven by external financing rather than internal value creation.
The erratic movement in total equity suggests a reliance on dilutive capital raises to offset persistent operating losses. Investors should monitor whether the recent stabilization in equity can be sustained without further significant dilution, given the company's lack of revenue-generating assets.
Based on recent SEC filings, the company's cash position has fluctuated significantly, reaching a low of $50,900 in 2024Q3 before rising to $7.3 million by 2025Q3, yet this remains insufficient to cover the high fixed costs associated with ongoing gene therapy research and development.
While the current ratio of 83.69 in 2025Q3 appears superficially strong, it is a byproduct of minimal current liabilities rather than a robust cash buffer. The company's history of near-zero cash balances suggests that liquidity remains a critical, ongoing risk that could force management into unfavorable financing terms.
According to historical balance sheet data, the company's retained earnings have consistently declined to -$19.8 million as of 2025Q3, reflecting the cumulative impact of pre-revenue operations and the high costs of maintaining a public listing following the recent merger with Redwoods Acquisition Corp.
The persistent negative retained earnings highlight the structural challenge of funding long-term biotechnology development through equity markets. The reliance on equity issuance to maintain operations suggests that shareholders face a high probability of continued dilution as the company attempts to reach clinical milestones.
As disclosed in recent filings, the company carries $2.3 million in goodwill on its balance sheet, which represents a significant portion of its $10.1 million in total assets, potentially overstating the tangible value available to creditors in the event of a liquidity crisis.
This goodwill, likely stemming from the SPAC merger, warrants further investigation as it provides no immediate utility for funding the company's cash-intensive research. If the underlying intellectual property fails to yield clinical success, this asset may be subject to impairment, further weakening the balance sheet.
Quick answers to the most common questions about buying KLTOW stock.
As of 2024, Klotho Neurosciences, Inc. (KLTOW) had total assets of $2.5M including $0.2M in current assets.
Klotho Neurosciences, Inc. (KLTOW) carries total debt of $0.3M, offset by $0.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Klotho Neurosciences, Inc. (KLTOW) has total shareholders' equity (book value) of $1.2M ($0.06 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Klotho Neurosciences, Inc. (KLTOW) reported a current ratio of 0.13x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.